Results 101 to 110 of about 1,026 (172)

Reply to Saeed et al. Comment on "Rinaldi et al. Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study. <i>Viruses</i> 2025, <i>17</i>, 251". [PDF]

Viruses
Caturano A, Rinaldi L, Izzi A.
europepmc   +1 more source

Cost-Effective Synthesis of Bule-OH: An Alternative to Bulevirtide for Hepatitis B and D Research

Pharmaceutical Fronts
Hongxiang Zhu, Haoju Hua, Yuanzhen Dong, Hongjiang Xu, Jun Feng   +4 more
doaj   +1 more source

Therapeutic vaccination strategy targeting the PreS1 region of L-HBsAg for HBV/HDV co-infection. [PDF]

JHEP Rep
Russell RA, Lok J, Harris JM, Tsukuda S, Rose LM, Charlton BG, Carey I, Agarwal K, Wing PAC, Biswas S, McKeating JA, Dicks MDJ.   +11 more
europepmc   +1 more source

Post-Translational Modifications of NTCP: A Regulatory Nexus for Bile Acid Transport and HBV Entry. [PDF]

Biomedicines
Yu F, Zhu Y, Li N, Peng Q, Ye F, Luo Q, Xia J, Hu X.   +7 more
europepmc   +1 more source

Comment on Rinaldi et al. Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study. <i>Viruses</i> 2025, <i>17</i>, 251. [PDF]

Viruses
Saeed MH, Zaheer MA, Kumar B, Ali A, Shaikh MA.   +4 more
europepmc   +1 more source

Impact of Handling Perception and Language Barriers on Virologic Response to Daily Subcutaneous Bulevirtide in Hepatitis D. [PDF]

Liver Int
Herta T, Dietz-Fricke C, Demir M, Sprinzl K, Pfeiffer KH, Grottenthaler JM, Buggisch P, Kremer WM, Reiter FP, Geier A, Schramm C, Merle U, Neumann-Haefelin C, Tacke F, Berg T, Wedemeyer H, Deterding K, Wiegand J.   +17 more
europepmc   +1 more source

Response-guided bulevirtide ± pegylated interferon alfa-2a: Long-term outcomes observed in the nationwide Austrian hepatitis D cohort study. [PDF]

JHEP Rep
Schwarz M, Hintersteininger M, Schwarz C, Panzer M, Pfisterer N, Loschko N, Hartl L, Dorn L, Laferl H, Trauner M, Stättermayer AF, Mandorfer M, Graziadei I, Maieron A, Moschen A, Aigner E, Stadlbauer V, Madl C, Aberle SW, Zoller H, Gschwantler M, Reiberger T, Jachs M.   +22 more
europepmc   +1 more source

Interaction between W41 of the hepatitis B virus preS1 surface peptide and Y146/F274 of the cellular receptor molecule Na⁺/taurocholate co-transporting polypeptide is essential for virus entry. [PDF]

Mol Pharmacol
Kunz S, Soppa L, Leidolf R, Neubauer A, Lütteke T, Glebe D, Geyer J.   +6 more
europepmc   +1 more source

Hope on the horizon: Emerging therapies for hepatitis D. [PDF]

World J Hepatol
Abbas Z, Abbas M.
europepmc   +1 more source

Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy

JHEP Reports
Adquate Mhlanga, Ori Wasserman, Pietro Lampertico, Scott J. Cotler, Harel Dahari   +4 more
doaj   +1 more source